Training Program in Cancer Pharmacology

癌症药理学培训计划

• 批准号: 6951501
• 负责人: Ian Alexander Blair
• 金额: $ 52.03万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-24 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6951501
• 关键词: career; curriculum; drug discovery /isolation; drug screening /evaluation; education evaluation /planning; experimental designs; health science manpower; health science profession; health science research; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; postgraduate education

DESCRIPTION (provided by applicant): Training Grant in Cancer Pharmacology. The purpose of the multidisciplinary Cancer Pharmacology training program is to provide predoctoral and postdoctoral students with a training environment that does not currently exist at the University of Pennsylvania. Drs. Blair (Program Director), Penning (Program Co-Director) and Assoian (Program Co-Director) have provided the sustained leadership required to develop a multidisciplinary program in molecular mechanisms of multi-stage carcinogenesis. There is now a real need for similar sustained leadership to be applied to the recruitment and training of both predoctoral and postdoctoral scientists in the multidisciplinary environment required for the field of cancer pharmacology. Major advances in the treatment of cancer patients in the next decade will result from multidisciplinary approaches in understanding of how malignant cells work at the molecular level and in designing novel therapeutic agents to disrupt these processes. Therefore, the proposed training program will help fill the current deficit of individuals qualified to develop the next generation of chemotherapeutic agents. The ultimate goal of the program is to provide training in cancer pharmacology that goes from laboratory to bedside and back again. Specifically, trainees will learn how cancer pharmacology can be used to identify new targets, how small molecules are synthesized and tested against these targets, how they are used in Phase I trials, how Phase I studies are developed into full clinical trials, and how epidemiology and pharmacogenetics are utilized to assess efficacy and lead to the discovery of new targets. Trainees will also receive specific training in how to project quantitative measures of drug effect from proof of concept in model systems into the rational selection of dosing in humans. These goals will be accomplished through the courses that are offered and the multidisciplinary research experiences that will be available from the faculty. The 26 faculty mentors with diverse complementary expertise are grouped into three programs: A. Pharmacology Discovery and Development. B. Cell and Molecular Cancer Pharmacology. C. Clinical Cancer Pharmacology. The trainees will have research mentors from two of these programs. The mentors on this proposed program have a very strong record of accomplishment as cancer researchers. They are Principal Investigators or Project Leaders on 68 NIH grants of which 39 (57%) are from NCI (27 RO-1s, 8 PO-1 Projects, 1 PO-1 Scientific Core, 1 P30 Scientific Core, 1 UO-1, 1 T-32). Apart from training grants, 11 of the mentors have NIH-funded (primarily through NCI) collaborative research grants. The mentors serve on Editorial Boards of 23 Journals and two of them are Journal Editors. Over the past 10-years, the mentors have trained 105 predoctoral students and 250 postdoctoral fellows; they currently have 52 predoctoral and 76 postdoctoral trainees in their laboratories. The mentors have clearly demonstrated that they have the scientific expertise and training experience to develop a new multidisciplinary training program in Cancer Pharmacology. Mentors have superb access to different patient populations through their association with 11 NCI-funded clinical programs. Furthermore, one of the mentors is Director of the General Clinical Research Center at the University of Pennsylvania (Dr. FitzGerald) and one is acting Director of the General Clinical Research Center at Children's Hospital of Philadelphia (Dr. Adamson). Both of these mentors have research programs with a focus on translational therapeutics and so they provide another outstanding training resource.

描述(申请人提供)：癌症药理学培训助学金。多学科癌症药理学培训计划的目的是为博士后和博士后学生提供宾夕法尼亚大学目前不存在的培训环境。布莱尔博士(项目主任)、潘宁博士(项目联席主任)和阿索安博士(项目联席主任)为开发多阶段致癌分子机制的多学科项目提供了所需的持续领导。现在确实需要在癌症药理学领域所需的多学科环境中对博士前和博士后科学家的招聘和培训采用类似的持续领导。未来十年癌症患者治疗方面的重大进展将源于多学科方法，即在分子水平上了解恶性肿瘤细胞的工作原理，并设计新的治疗剂来扰乱这些过程。因此，拟议的培训计划将有助于填补目前有资格开发下一代化疗药物的个人的短缺。该计划的最终目标是提供从实验室到床边再回来的癌症药理学培训。具体地说，学员将学习如何利用癌症药理学来确定新的靶点，如何合成小分子并针对这些靶点进行测试，如何将它们用于第一阶段试验，如何将第一阶段研究发展为全面的临床试验，以及如何利用流行病学和药物遗传学来评估疗效和发现新的靶点。受训人员还将接受具体培训，了解如何将药物效果的量化措施从模型系统中的概念验证转化为人体剂量的合理选择。这些目标将通过提供的课程和教师提供的多学科研究经验来实现。26名具有不同互补专业知识的教师导师被分成三个项目：A.药理学、发现和开发。B.细胞和分子癌症药理学。C.临床抗癌药理学。受训者将有来自其中两个项目的研究导师。作为癌症研究人员，这一计划的导师有着非常出色的成就。他们是首席调查员或项目负责人 68项NIH补助金，其中39项(57%)来自NCI(27个RO-1、8个PO-1项目、1个PO-1科学核心、1个P30科学核心、1个UO-1、1个T-32)。除了培训补助金，其中11名导师还获得了NIH资助(主要是通过NCI)的合作研究补助金。这些导师在23家期刊的编辑委员会任职，其中两人是期刊编辑。在过去的10年里，导师们培养了105名博士后学员和250名博士后研究员；他们的实验室目前有52名博士后学员和76名博士后学员。导师们已经清楚地表明，他们拥有开发新的癌症药理学多学科培训计划的科学专业知识和培训经验。导师通过他们与NCI资助的11个临床项目的联系，可以很好地接触到不同的患者群体。此外，其中一位导师是宾夕法尼亚大学综合临床研究中心主任(菲茨杰拉德博士)，另一位是费城儿童医院综合临床研究中心代理主任(亚当森博士)。这两位导师都有专注于翻译疗法的研究项目，因此他们提供了另一种出色的培训资源。